Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cardiovascular disease

Atherosclerosis

Gremlin 1 (GREM1); macrophage migration inhibitory factor (MIF)

In vitro and mouse studies suggest a GREM1 fusion protein could be used to antagonize MIF and treat atherosclerosis. In an apolipoprotein E (APOE)-deficient mouse model of atherosclerosis, Grem1 and Mif colocalized to atherosclerotic lesions, and in vitro binding assays showed that GREM1 binds to MIF. In ApoE-deficient mice fed a cholesterol-rich diet, a Grem1 fusion protein with better pharmacokinetics than native Grem1 decreased levels of Mif, numbers of macrophages in atherosclerotic lesions and formation of lesions compared with a control fusion protein. Next steps include identifying GREM1-MIF interaction sites.

SciBX 6(39); doi:10.1038/scibx.2013.1096
Published online Oct. 10, 2013

Patented application filed; available for licensing

Muller, I. et al. J. Biol. Chem.; published online Sept. 3, 2013;
doi:10.1074/jbc.M113.477745
Contact: Meinrad Gawaz, Eberhard Karls University of Tuebingen, Tuebingen, Germany
e-mail:

meinrad.gawaz@med.uni-tuebingen.de